Skip to main content
. Author manuscript; available in PMC: 2016 Jun 1.
Published in final edited form as: Neuropharmacology. 2015 Feb 3;93:15–27. doi: 10.1016/j.neuropharm.2015.01.017

Table 3.

Individual plasma pharmacokinetic parameters of TG6-10-1 in male SD rats.

Animal ID: Tmax (hr) Cmax (ng/mL) AUClast (hr*ng/mL) AUCINF (hr*ng/mL) T1/2 (hr)
1 0.25 595 1401 1463 1.89
2 0.08 567 1423 1502 1.92
3 2.00 404 1913 2528 3.69
Mean (ip) 0.78 522 1579 1831 2.50
4 1.00 627 1252 1262 1.54
5 0.50 283 569 570 0.78
6 0.50 530 1102 1180 3.5
Mean (po) 0.67 480 974 1004 1.94

Rats 1-3 received a single intraperitoneal (10 mg/kg) administration of TG6-10-1. Rats 4-6 received a single oral (20 mg/kg) administration of TG6-10-1. Tmax = time to peak plasma concentration; Cmax = peak plasma concentration; AUClast = area under the plasma concentration versus time curve from zero to the last quantifiable concentration; AUCinf = estimated area under the plasma concentration versus time curve from zero to infinity; T1/2 = terminal half-life